Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Coloplast on the acquisition of Atos Medical
Mandate

Vinge advises Coloplast on the acquisition of Atos Medical

November 11, 2021 Employment and Benefits Real Estate and Construction Banking and Finance Corporate Crime & Compliance IT, Telecommunications and Outsourcing Intellectual Property M&A

Vinge advises Danish healthcare company Coloplast on its acquisition of Atos Medical, the global market leader in laryngectomy for EUR 2.155 billion (around DKK 16 billion) from PAI Partners, a global private equity firm headquartered in Paris. Closing of the transaction is subject to customary regulatory approvals and anticipated to occur in Q2 2021/22.

Vinge’s team primarily consisted of Matthias Pannier, Ulrich Ziche, Vilhelm Rondahl, Clara Sohlberg and Julia Hagelberg (M&A), Klara Secher and Axel Lennartsson (IP), Lisa Hörnqvist and Mario Saad (Agreements and IT), Karl-Hugo Engdahl and Karolina Fuhrman (GDPR), Tove Lövgren Frisk (Compliance), Jolinn Uhlin and Michaela Ådén (Banking & Financing), Elin Broman (Employment) and Lina Österberg and Ulf Pyk (Real Estate). Kromann Reumert acted as lead counsel for Coloplast.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026